-
公开(公告)号:US07470702B2
公开(公告)日:2008-12-30
申请号:US10577033
申请日:2004-10-14
IPC分类号: A01N43/40 , A61K31/435 , C07D213/00
CPC分类号: C04B35/632 , C07D401/12 , C07D403/12 , C07D409/14
摘要: Novel compounds of the formula I in which R1, R1′, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated. Further, the compounds of formula I can be used as, for example, inhibitors of tyrosine kinases, for example TIE-2 , and can be employed, for example, for the treatment of tumours or other diseases.
摘要翻译: 其中R1,R1',L,E,G,M,Q,U,R2,m,p和q具有所示含义的式I的新型化合物。 此外,式I化合物可用作例如酪氨酸激酶抑制剂,例如TIE-2,并且可用于例如治疗肿瘤或其它疾病。
-
公开(公告)号:US20070244135A1
公开(公告)日:2007-10-18
申请号:US11578375
申请日:2005-03-17
IPC分类号: A61K31/519 , C07D471/04
CPC分类号: C07D471/04
摘要: Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
摘要翻译: 式(I)的化合物,其中R 6,R 7,R 8,R 9和/或 X具有权利要求1中所示的含义,是酪氨酸激酶,特别是TIE-2和Raf激酶的抑制剂,特别可用于治疗肿瘤。
-
公开(公告)号:US20070066660A1
公开(公告)日:2007-03-22
申请号:US10577033
申请日:2004-10-14
IPC分类号: A61K31/4439 , C07D403/02
CPC分类号: C04B35/632 , C07D401/12 , C07D403/12 , C07D409/14
摘要: The invention relates to the novel compounds of formula (I) wherein R1, R1, L, E, G, M, Q, U, R2, m, p and q are defined as in claim 1. The novel compounds are tyrosinkinase inhibitors, especially TIE-2 inhibitors, and Raf kinase inhibitors and can be used in the treatment of tumors.
摘要翻译: 本发明涉及式(I)的新化合物,其中R 1,R 1,L,E,G,M,Q,U,R 2 m,p和q如权利要求1中所定义。新化合物是酪氨酸激酶抑制剂,特别是TIE-2抑制剂和Raf激酶抑制剂,可用于治疗肿瘤。
-
公开(公告)号:US08846694B2
公开(公告)日:2014-09-30
申请号:US12996786
申请日:2009-05-13
申请人: Timo Heinrich , Mireille Krier , Thorsten Knoechel , Alfred Jonczyk , Frank Zenke , Holger Enderle
发明人: Timo Heinrich , Mireille Krier , Thorsten Knoechel , Alfred Jonczyk , Frank Zenke , Holger Enderle
IPC分类号: A61K31/52 , C07D403/04 , C07D473/34 , C07D513/04 , A61K9/19 , C07D487/04 , A61K9/02 , A61K9/00 , A61K9/20 , C07D471/04
CPC分类号: C07D473/34 , A61K9/0019 , A61K9/0048 , A61K9/02 , A61K9/19 , A61K9/2018 , C07D471/04 , C07D487/04 , C07D513/04
摘要: Compounds of the formula (I), in which R, X, Y, Z, R3 and R4 have the meanings indicated in claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
摘要翻译: 其中R,X,Y,Z,R 3和R 4具有权利要求1所示含义的式(I)化合物是甲硫氨酸氨基肽酶的抑制剂,可用于治疗肿瘤。
-
公开(公告)号:US08815893B2
公开(公告)日:2014-08-26
申请号:US13580277
申请日:2011-01-10
申请人: Alfred Jonczyk , Dieter Dorsch , Frank Zenke , Christiane Amendt
发明人: Alfred Jonczyk , Dieter Dorsch , Frank Zenke , Christiane Amendt
IPC分类号: C07D215/38 , A61K31/04
CPC分类号: C07D471/04 , C07D453/02 , C07D519/00
摘要: Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
摘要翻译: 其中X,R 1,R 2,R 3,R 4,W 1,R 2,R 3,R 4,W 1,W 2,W 3,W 5和W 6具有权利要求1的含义的式(I)的新颖的杂芳基氨基萘啶衍生物是ATP消耗蛋白质的抑制剂, ,用于治疗肿瘤。
-
46.
公开(公告)号:US20120225875A1
公开(公告)日:2012-09-06
申请号:US13508090
申请日:2010-10-12
申请人: Alfred Jonczyk , Christiane Amendt , Frank Zenke
发明人: Alfred Jonczyk , Christiane Amendt , Frank Zenke
IPC分类号: A61K31/4709 , A61K31/506 , C07D401/14 , A61K31/496 , A61K31/53 , C07D471/04 , A61K31/498 , A61K31/501 , C07D413/14 , A61K31/5377 , A61P35/00 , A61P35/04 , A61P31/18 , A61P25/28 , A61P9/10 , A61P29/00 , A61P17/02 , A61P9/00 , A61P19/08 , A61P25/00 , A61P25/02 , C12N9/99 , C07D401/12
CPC分类号: C07D401/12 , C07D401/14 , C07D471/04
摘要: Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
摘要翻译: 其中X,Z,Het,R 1,R 2,R 3和R 4具有权利要求1的含义的式(I)的新颖的杂芳基氨基喹啉衍生物是ATP消耗蛋白质的抑制剂,并且可以用于治疗肿瘤 。
-
公开(公告)号:US08242128B2
公开(公告)日:2012-08-14
申请号:US10573176
申请日:2004-09-01
IPC分类号: A61K31/506 , A61K31/423 , A61K31/4465 , C07D239/42 , C07D413/10 , C07D263/58
CPC分类号: C07D263/58 , C07D413/12
摘要: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I)
摘要翻译: 本发明涉及式1的化合物,其作为用于治疗由血管发生介导或繁殖引起的疾病,特别是肿瘤和/或疾病的药物的生产和用途。 式1的化合物是酪氨酸激酶,特别是TIE-2和VEGFR以及Raf-激酶的有效抑制剂。 (一世)
-
公开(公告)号:US07759302B2
公开(公告)日:2010-07-20
申请号:US10544625
申请日:2004-01-14
申请人: Alfred Jonczyk , Ulrich Groth , Gunther Zischinsky
发明人: Alfred Jonczyk , Ulrich Groth , Gunther Zischinsky
IPC分类号: A61K38/08
摘要: The invention relates to novel peptides which are biologically active as ligands of blood platelet integrin GPIIbIIIa and the αv integrins, preferably the avβs and αvβ3 integrin, having the formula (I): R1-Arg-X-Asp-Leu-Asp-Ser-Leu-Arg-R2 (I), in which R1 denotes H, acetyl or acyl and R2 denotes -Oh, OR3NH2, NHR3, N(R3)2 R3 denotes atkyl, aralkyl, aryl, Het and X denotes an amino acid of the formula (II), in which A denotes (CH2)n R4 denotes H, alkyl, aralkyl or aryl, and n denotes 1, 2, 3, 4, 5 or 6, and the amino acid of the formula (II) is bonded to the adjacent Arg via a peptide bond of the α-amino group and to the α-amino group of the adjacent Asp via a peptide bond of the α-carboxyl group.
摘要翻译: 本发明涉及作为血小板整合蛋白GPIIbIIIa和αv整联蛋白的配体的生物活性的新肽,优选具有式(I)的化合物和αv&bgr 3整联蛋白:R1-Arg-X-Asp-Leu- Asp-Ser-Leu-Arg-R2(I)其中R1表示H,乙酰基或酰基,R2表示-Oh,OR3NH2,NHR3,N(R3)2 R3表示烷基,芳烷基,芳基,Het,X表示 (II)的氨基酸,其中A表示(CH 2)n R 4表示H,烷基,芳烷基或芳基,n表示1,2,3,4,5或6,并且式(II)的氨基酸 II)通过α-氨基的肽键和相邻的Asp的α-氨基经由α-羧基的肽键与相邻的Arg键合。
-
公开(公告)号:US08846931B2
公开(公告)日:2014-09-30
申请号:US13808369
申请日:2011-06-07
IPC分类号: C07D401/14 , A61K45/06 , C07D213/74 , A61K31/496 , C07D471/04 , A61K31/5377 , A61K31/444 , A61K31/4545
CPC分类号: C07D401/14 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D213/74 , C07D471/04
摘要: The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.
摘要翻译: 本发明涉及式(I)的新型联吡啶衍生物和其中ATP消耗蛋白质如激酶的信号转导的抑制,调节和/或调节起到特别是TGF-β抑制剂的作用的用途 受体激酶,以及这些化合物用于治疗激酶诱导的疾病,特别是用于治疗肿瘤的用途。
-
公开(公告)号:US20140038960A1
公开(公告)日:2014-02-06
申请号:US14046703
申请日:2013-10-04
IPC分类号: C07D401/14 , C07D471/04 , C07D413/14
CPC分类号: C07D471/04 , A61K31/4375 , C07D401/14 , C07D413/14 , C07D519/00
摘要: Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
摘要翻译: 其中R 1,R 2,W 1,W 3,W 5和W 6具有权利要求1的含义的式(I)的新型杂芳基 - [1,8]二氮杂萘衍生物是ATP消耗蛋白质的抑制剂, 用于治疗肿瘤。
-
-
-
-
-
-
-
-
-